Various biomarkers such as mutational burden [3, 4], the presence of tumor-infiltrating lymphocytes [5, 6], and interferon-gamma signature [7] have been suggested for predicting the response to anti-PD-1/PD-L1 inhibitors; among these, PD-L1 expression in tumor cells is a promising and simple predictive biomarker [8, 9]. This evidence concerns the gene IFNG and neoplasm.